Extensive Stage Small Cell Lung Cancer

SEP 8, 2026 · PHASE 3 TRIAL

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

ClinicalTrials.gov

This is a Phase 3 clinical trial registry record with no reported results; the study is active but not recruiting, and efficacy outcomes have not yet been posted.

AUG 14, 2026 · PHASE 3 TRIAL

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

ClinicalTrials.gov

This is a Phase 3 trial registration with no results reported; the study is actively recruiting and outcome data are not yet available.

AUG 11, 2026 · PHASE 1 TRIAL

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

ClinicalTrials.gov

Phase 1 dose-escalation study with planned enrollment of 24 participants; designed to establish safety and recommended Phase 2 dose, not to demonstrate efficacy or clinical benefit.

AUG 7, 2026 · INTERVENTIONAL STUDY

Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

ClinicalTrials.gov

This is a clinical trial registry record for an expanded access program with no results posted; it describes a planned intervention pathway, not clinical evidence of efficacy or safety.

AUG 7, 2026 · PHASE 1 TRIAL

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

ClinicalTrials.gov

This is a Phase 1 trial registration with no results yet posted; it describes a planned study of autologous B7-H3 CAR T cells in recurrent/refractory small cell lung cancer, currently not yet recruiting.

AUG 3, 2026 · PHASE 1/2 TRIAL

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

ClinicalTrials.gov

This is an active interventional trial combining a radiopharmaceutical with chemotherapy and immunotherapy in ES-SCLC; no results are posted in this registry record, and the study aims only to establish safety and preliminary efficacy.